Trevi Hits 52-Week High After Public Offering Pricing

Trevi Therapeutics priced an underwritten public offering of 11.6 million shares of common stock at $13 per share. The deal increases share count and is typically dilutive to existing holders, though it also raises capital for the clinical-stage biotech. The announcement is factual and likely stock-specific rather than broadly market-moving.

Analysis

Trevi Therapeutics priced an underwritten public offering of 11.6 million shares of common stock at $13 per share. The deal increases share count and is typically dilutive to existing holders, though it also raises capital for the clinical-stage biotech. The announcement is factual and likely stock-specific rather than broadly market-moving.